176
|
Kim H, Kim M, Ahn S, Son B, Kim S, Jung K, Ahn J, Kim H, Gong G. Do stem cell markers have significant implication in breast cancer? Immunohistochemical study for CD44 and CD24. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-5058] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #5058
Background: We reported that breast cancer expressing CD44+CD24-/low showed a favorable prognosis in contrary to the in vitro/in vivo studies. We further followed this data up to 99 months and analyzed it according to CD44 expression, CD24 expression and hormone expression.
 Design: immunohistochemical stainings for CD44s and CD24 as well as prognostic markers including estrogen receptor, progesterone receptor, p53, and Her2/neu were done using tissue microarray blocks containing 645 consecutive cases of invasive breast carcinomas from 1993 to 1998. Mean follow up periods were 99.5 months. Cases were categorized into four subgroups (CD44-/CD24+, CD44+/CD24+, CD44-/CD24-, CD44+/CD24-) based on the immunohistochemical staining results and compared them with clinicopathologic parameters. Immunostainings for CD44s and CD24 interpreted as positive if at least 1% of tumor cells show distinct membranous and/or cytoplasmic stainings. In the positive group of CD24, we categorized it as three subgroups according to the degree of positivity.
 Results: CD44+CD24-/low group showed inversely associated with lymph node metastasis and the tumor stage than other subgroups (p=0.001 and p=0.018, respectively). And CD44+CD24-/low group was showed an increase in disease free survival and overall survival (p=0.003, p=0.002) In the subgroup analysis of CD24 expression (0, grade 1, grade 2, grade 3), the incidence of metastasis and death was more frequently observed in the cases with the higher expression of CD24. (DFS: p=0.03, OS: p=0.001). With respect to the CD44, CD44- group showed frequent metastasis and death (p=0.01, both) however, for the receptor positive groups, not CD44 but CD24 expression resulted negatively to the overall survival significantly(p=0.01, Relative risk=1.90) on multivariate analysis. For the receptor negative groups, especially triple negative group, lack of CD44 expression made overall decreased to 50%(p=0.03, hazard ratio=0.5)
 Conclusion: In contrast to cell line studies, CD44+CD24-/low phenotype is considered a favorable prognostic subgroup of breast cancer associated with less frequent nodal metastasis, lower tumor stage and infrequent distant metastasis. For receptor positive breast caner, CD24 expression effect DFS, OS significantly, and For receptor negative group, especially triple negative breast cancer, Lack of CD44 expression made and effect OS inversely.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 5058.
Collapse
|
177
|
Im S, Lee K, Lee E, Kwon Y, Noh D, Park I, Ahn J, Ahn J, Kim J, Nam B, Ro J. Remarkable complete pathologic response rate after preoperative paclitaxel, gemcitabine, and trastuzumab chemotherapy in HER2 positive stage II/III breast cancer: a phase II multicenter study. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-5105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #5105
Background: Preoperative paclitaxel (P) and gemcitabine (G) combination therapy given on D1/D8 every 3 weeks (wks) for 4 cycles was well tolerated and effective in stage II/III breast cancer (BC) in our previous phase II study, with an 18% pathological complete response (pCR) rate. Adding trastuzumab (H) to the preoperative chemotherapy increases both of the clinical and pathological response rates in HER2 positive BC patients (pts). Thus far, the highest pCR rate reported in the literature was obtained with anthracycline-based regimens in combination with trastuzumab. This study evaluated whether non-anthracycline combination chemotherapy with PGH could improve the pCR rate in HER2 positive BC. Methods: HER2 positive, stage II/III BC pts with cytologically confirmed axillary lymph node (LN), ≥ 18 years of age, with adequate organ function, and good performance status were eligible. No prior therapy was allowed. Pts received H intravenously (iv) at 4 mg/kg on D1 of the first cycle with subsequent weekly doses of 2 mg/kg in combination with P 80 mg/m2 and G 1,200 mg/m2, iv, on D1/D8 every 3 wks for 6 cycles. Within 2 wks postoperatively, patients received H 6 mg/kg every 3 wks for 11 cycles with tamoxifen or an aromatase inhibitor for 5 years if indicated. All pts received postoperative radiation therapy. Initial evaluation included sonogram and MRI of the breast, MUGA scan, or echocardiogram, and PET-CT. Results: All 53 planned pts were enrolled between April 2007 and February 2008. The median age was 43 years (range, 26–61 years), the median primary tumor size by sonogram was 5.3 cm (range, 2.0 to > 12 cm) with 89 % ≥ stage IIIA, 42% T3/T4, and 28% N3. Twenty four tumors (45%) were multiple and 20 tumors (38%) were ER positive. By May 2008, 47 patients completed surgery with a 74% breast conservation rate. Twenty-eight of 47 (60%; 95% CI, 45-72) patients achieved pCR in both the tumor and lymph node, with 68% (32/47; 95% CI, 54-80) pCR in the primary tumor, and 77% (36/47; 95% CI, 63-86) pCR in the axillary LN. Median metastatic focus in 21 positive LNs (n=11 pts) was 1 mm (range, <1–13mm). Grade III/IV adverse events (AE) were neutropenia (53%), febrile neutropenia (4%), and transient elevation of AST/ALT (9%). After 6 cycles of PGH chemotherapy, all patients maintained above normal LVEF. Conclusions: A remarkably high pCR was obtained by non-anthracyline based PGH combination therapy for HER2 positive stage II/III breast cancer. This combination is well tolerated with mild degree of AEs.
 Supported by NCC Grant No 0610240-3. Trastuzumab, paclitaxel, and gemcitabine were supplied by Roche, CJ Cheiljedang CO., and Eli Lilly and CO., respectively.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 5105.
Collapse
|
178
|
Choi J, Kim K, Kim W, Lee S, Lim H, Cho E, Han B, Kim Y, Ahn J, Im Y, Lee J, Nam S, Yang J. Evaluation of response to neoadjuvant chemotherapy in primary breast cancer using PET. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-4019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #4019
Purpose
 To estimate the usefulness of PET scan to assess the response of neoadjuvant chemotherapy, PET scan results were compared with conventional imaging modalities(US and MRI).
 Patients and Methods
 Fourty-one patients undergoing neoadjuvant chemotherapy between December 2004 and March 2008 were included. PET scan was performed before and after chemotherapy. Pathologic results were classified into two groups; pathological complete response(pCR) and non-pCR. Clinical responses were assessed with the results of imaging modalities such as post-chemotherapy size or pSUV(postTx), size difference between treatment(delta) and reduction rate(RR) of size or pSUV, and they are compared with postoperative pathologic results.
 Results
 7 out of 41 patients (17.1%) had pCR. The results of US shows that postTx size (1.7±1.5cm) of pCR was not dfferent from those of non-pCR (3.6±3.0cm), and the delta (3.1±1.9cm) and RR (67.7±29.1%) of pCR were higher than those of non-pCR (1.3±1.3cm, 31.0±25.4%), respectively. As a result of MRI, postTx size, delta, RR of pCR was differ from those of non-pCR (1.0±1.7cm vs 2.8±1.7cm p<0.05; 4.5±1.0cm vs 2.3±1.8cm, p<0.05; 88.0±20.8% vs 44.6±24.7%, p<0.01). In PET scan, only postTx pSUV of pCR was differ from that of non-pCR (1.4±1.3 vs 5.3±8.3cm, p<0.05). As a result of receiver operating characteristic curve analyses for the prediction of pathological response of breast cancer, area under curve values (95% confidence interval) of US, MRI, PET for delta were 0.83(0.69∼0.98), 0.91(0.80∼1.01), 0.62(0.38∼0.86), and those of RR were 0.80(0.60∼0.99), 0.90(0.77∼1.02), 0.72(0.47∼0.96), respectively
 Conclusions
 We suggest that MRI is useful method to evaluate the response of neoadjuvant chemotherapy. Although PET scan shows less effective for evaluating the response of chemotherapy than MRI, PET scan with the ability to detect the distant metastatic lesions may be helpful to decide the proper management plans for advanced breast cancer.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 4019.
Collapse
|
179
|
Seon K, Ahn J, Kwak H. The accelerated ripening of cholesterol-reduced Cheddar cheese by crosslinked β-cyclodextrin. J Dairy Sci 2009; 92:49-57. [DOI: 10.3168/jds.2008-1319] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
180
|
Xu H, Lee H, Hwang B, Nam J, Kang H, Ahn J. Kinetics of microbial hydrogenation of free linoleic acid to conjugated linoleic acids. J Appl Microbiol 2008; 105:2239-47. [DOI: 10.1111/j.1365-2672.2008.03937.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
181
|
Schroeder S, Ahn J, Seviour R. Ecophysiology of polyphosphate-accumulating organisms and glycogen-accumulating organisms in a continuously aerated enhanced biological phosphorus removal process. J Appl Microbiol 2008; 105:1412-20. [DOI: 10.1111/j.1365-2672.2008.03857.x] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
182
|
Kim S, Park S, Ahn J, Kwak H. Properties of Cholesterol-reduced Block-type Process Cheese Made by Crosslinked β-Cyclodextrin. Korean J Food Sci Anim Resour 2008. [DOI: 10.5851/kosfa.2008.28.4.463] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
|
183
|
Sohn Y, Ahn H, Ahn J. 381: Is the Halo Sign Useful in Hemorrhagic Shock? Ann Emerg Med 2008. [DOI: 10.1016/j.annemergmed.2008.06.408] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
184
|
Farley H, Canning J, Ahn J, Lake A, Reed J. 191: Absence of Racial Disparities in Emergency Department Analgesia Administration. Ann Emerg Med 2008. [DOI: 10.1016/j.annemergmed.2008.06.208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
185
|
Ahn J, Kim NJ, Choung HK, Hwang SW, Sung M, Lee MJ, Khwarg SI. Frontalis sling operation using silicone rod for the correction of ptosis in chronic progressive external ophthalmoplegia. Br J Ophthalmol 2008; 92:1685-8. [DOI: 10.1136/bjo.2008.144816] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
186
|
Lee D, Kim S, Park K, Kim J, Lee J, Shin S, Kang J, Suh C, Ahn M, Ahn J. A randomized open-label study of gefitinib versus docetaxel in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who have previously received platinum-based chemotherapy. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.8025] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
187
|
Chang H, Rha S, Jeung H, Im C, Ahn J, Kwon W, Yoo N, Roh J, Chung H. Association of MDR-1 gene polymorphism 2677G/T(A) and 3435C/T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.14654] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
188
|
Cheon S, Rha S, Jeung H, Im C, Kim S, Kim H, Ahn J, Roh J, Noh S, Chung H. Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.4580] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
189
|
Yi S, Uhm J, Cho E, Lee S, Park M, Jun H, Park Y, Ahn J, Im Y, Kang W, Park K. Clinical outcomes of metastatic breast cancer patients with triple-negative phenotype who received platinum-containing chemotherapy. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.1008] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
190
|
Hong S, Shin S, Im C, Jeung H, Rha S, Chung H, Roh J, Lee S, Ryoo H, Ahn J. Adjuvant 5-fluorouracil and leucovorin with or without OK-432 in colorectal cancer: A single-institutional study of long-term follow-up. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.15128] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
191
|
Shin S, Park Y, Kim T, Oh D, Shim B, Lee K, Lee M, Kim Y, Kim Y, Ahn J. Multicenter phase II trial of S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable colorectal cancer. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.15057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
192
|
Uhm J, Hong J, Choi M, Kim K, Han J, Kim J, Shim Y, Kwon O, Ahn J, Ahn M, Park K. External validation of proposals for the revision of the TNM stage groupings by the IASLC lung cancer staging project in Korean non-small cell lung cancer patients. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.22140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
193
|
Kim H, Uhm J, Ahn H, Yi J, Han J, Choi Y, Kim K, Kim H, Ahn J, Ahn M, Park K. Gender difference as a prognostic factor in patients with non-small cell lung cancer. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.22155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
194
|
Lee H, Ahn M, Ahn J, Kwon J, Lee S, Bae S, Kim B, Kim H, Hong D, Park K. Pemetrexed monotherapy in patients with advanced non-small cell lung cancer who have had prior chemotherapy: A prospective phase II trial. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.19137] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
195
|
Im C, Jung H, Rha S, Ahn J, Shin S, Noh S, Roh J, Chung H. Comparison of taxane-based (docetaxel or paclitaxel) regimens combined with 5-fluorouracil continuous infusion and low dose leucovorin for advanced gastric carcinoma: Analysis of two phase II trials. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.15679] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
196
|
Jeung H, Im C, Rha S, Ahn J, Shin S, Noh S, Roh J, Chung H. A randomized phase II trial of docetaxel plus S-1 versus docetaxel plus cisplatin in advanced gastric cancer as a first-line treatment. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.4534] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
197
|
Wang Y, Yoon SF, Liu CY, Ngo CY, Ahn J. Temperature and excitation density dependent photoluminescence of sputtering-induced GaAs/AlGaAs quantum dots. NANOTECHNOLOGY 2008; 19:015602. [PMID: 21730537 DOI: 10.1088/0957-4484/19/01/015602] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
GaAs/AlGaAs quantum dots (QDs) are fabricated by low-energy ion beam sputtering and molecular beam epitaxy (MBE) re-growth. Temperature (6.5-78 K) and excitation power density (0.49-3.06 W cm(-2)) dependent photoluminescence (PL) are presented and discussed in detail. The low-temperature PL emission at 720 nm is attributed to GaAs QDs with height of ∼6.1 nm and base width of ∼23 nm, calculated based on the quantum box model with infinite potential barrier. The calculated QD dimensions are in good agreement with those obtained from atomic force microscopy (AFM) analysis. Nonradiative recombination and Auger-assisted recombination are found to be the main PL quenching mechanisms at high temperature.
Collapse
|
198
|
Han EM, Kim SH, Ahn J, Kwak HS. Comparison of Cholesterol-reduced Cream Cheese Manufactured Using Crosslinked 棺-Cyclodextrin to Regular Cream Cheese. ASIAN-AUSTRALASIAN JOURNAL OF ANIMAL SCIENCES 2008. [DOI: 10.5713/ajas.2008.70189] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
199
|
Ahn J, Albanes D, Peters U, Schatzkin A, Lim U, Freedman M, Chatterjee N, Andriole GL, Leitzmann MF, Hayes RB. Dairy Products, Calcium Intake, and Risk of Prostate Cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev 2007; 16:2623-30. [DOI: 10.1158/1055-9965.epi-07-0601] [Citation(s) in RCA: 102] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
200
|
Wang Y, Yoon SF, Ngo CY, Ahn J. Surface Morphology Evolution of GaAs by Low Energy Ion Sputtering. NANOSCALE RESEARCH LETTERS 2007; 2:504. [PMCID: PMC3246606 DOI: 10.1007/s11671-007-9090-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/18/2007] [Accepted: 08/17/2007] [Indexed: 05/31/2023]
Abstract
Low energy Ar+ion sputtering, typically below 1,200 eV, of GaAs at normal beam incident angle is investigated. Surface morphology development with respect to varying energy is analyzed and discussed. Dot-like patterns in the nanometer scale are obtained above 600 eV. As the energy approaches upper eV range regular dots have evolved. The energy dependent dot evolution is evaluated based on solutions of the isotropic Kuramoto-Sivashinsky equation. The results are in agreement with the theoretical model which describes a power law dependency of the characteristic wavelength on ion energy in the ion-induced diffusion regime.
Collapse
|